Fox Run Management L.L.C. Makes New Investment in Halozyme Therapeutics, Inc. $HALO

Fox Run Management L.L.C. bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, Holdings Channel.com reports. The fund bought 16,222 shares of the biopharmaceutical company’s stock, valued at approximately $844,000.

Other large investors also recently bought and sold shares of the company. Wealth Preservation Advisors LLC acquired a new stake in Halozyme Therapeutics in the first quarter valued at approximately $32,000. SVB Wealth LLC purchased a new position in shares of Halozyme Therapeutics during the 1st quarter valued at approximately $33,000. Brooklyn Investment Group lifted its position in shares of Halozyme Therapeutics by 1,558.1% during the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 670 shares in the last quarter. CWM LLC grew its stake in Halozyme Therapeutics by 46.3% in the 1st quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock valued at $88,000 after acquiring an additional 438 shares during the period. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Halozyme Therapeutics in the 1st quarter worth $89,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Down 0.2%

Shares of NASDAQ HALO opened at $68.24 on Monday. The stock has a market cap of $8.02 billion, a PE ratio of 15.62, a P/E/G ratio of 0.35 and a beta of 1.18. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $79.50. The company has a 50-day moving average of $70.66 and a 200 day moving average of $62.89.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The business had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. During the same period in the previous year, the firm posted $1.27 EPS. The business’s revenue for the quarter was up 22.1% compared to the same quarter last year. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HALO has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, October 21st. Morgan Stanley reduced their price target on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research report on Monday, October 20th. Citizens Jmp raised their price target on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a research note on Tuesday, November 4th. Benchmark boosted their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Finally, Zacks Research downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Seven analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $75.00.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CFO Nicole Labrosse sold 2,227 shares of the business’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $77.95, for a total transaction of $173,594.65. Following the transaction, the chief financial officer owned 22,079 shares of the company’s stock, valued at approximately $1,721,058.05. The trade was a 9.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $75.24, for a total transaction of $150,480.00. Following the sale, the director owned 44,952 shares of the company’s stock, valued at approximately $3,382,188.48. The trade was a 4.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 108,227 shares of company stock worth $7,779,595 in the last three months. 2.40% of the stock is owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.